Home | Contact Us

Roskamp Institute Patients, Families and Friends Healthcare Professionals Clinical Operations
Roskamp Institute
About Us How to Help News Careers Better science. Real discovery.

May 25, 2011

The Roskamp Institute Receives Golden Appreciation Award From Area Agency on Aging For Southwest Florida

SARASOTA, Fla., -- The Roskamp Institute has been named Golden Appreciation Award Winner during an annual luncheon hosted by the Area Agency on Aging for Southwest Florida. Now in its 17th year, the annual awards program recognizes contributions made by outstanding organizations and individuals in the aging network.

James, Humphrey, COO of Roskamp Institute, accepted the award on behalf of the scientific team at the Institute which is based in Sarasota. Roskamp's two lead researchers, Dr. Michael Mullan and Dr. Fiona Crawford were key members of a team of scientists who, in the early 1990s, discovered that the onset of Alzheimer’s was directly related to the accumulation of a protein called beta-amyloid.

"Our team of researchers has identified specific inflammatory chemicals that play a key role in promoting the production of the toxic protein, beta-amyloid, and that this in turn promotes inflammation," said Humphrey. "Alzheimer's disease is the consequence of a destructive cycle of inflammation where inflammatory chemicals interact with each other, causing damage and finally death to neurons in the brain."

Left to Right: James Humphrey, COO, Roskamp Institute; Joann Westbrook, Board Member, Area Agency on Aging for SW Florida; Steve Klindt, Director of Development, Roskamp Institute; Leigh Shield, Executive Director of the Area Agency on Aging for Southwest Florida.

Roskamp researchers have also discovered that Nilvadipine, a drug approved in Europe for treatment of mild hypertension, can stop the accumulation of the amyloid proteins implicated in Alzheimer’s disease. Last year, the Institute completed Phase I/II clinical trials in Europe regarding the safety of this new Alzheimer's disease drug. A large-scale Phase III efficacy study of Nilvadipine with 500 Alzheimer’s disease patients has just been approved for funding in Europe.

The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders. The Institute utilizes a broad range of scientific approaches to understanding the causes of -- and potential therapies for -- these disorders with an emphasis on Alzheimer's disease.

For more information: www.rfdn.org
Contact: Steve Klindt
Tel: 941-752-2949
Email: sklindt@roskampinstitute.org


Top | Home